Health officials have given a life-extending drug the green light for widespread NHS, giving hope to thousands of men facing a "death sentence" from prostate cancer.
The National Institute for Health and Care Excellence (Nice) said the drug enzalutamide, also known as xtandi, should be considered for use in the treatment of men with hormone relapsed prostate cancer that has spread to other parts of the body.
Nice said in its draft guidance that it was pleased to recommend the drug, which is manufactured by Astellas Pharma, for patients who have few other treatment options left.
More top news
A comedy drama series which details the lives of Russian expats in London will air tonight.
A 65-year-old man was attacked by a shark in Australia on Friday, leaving him with serious leg injuries.
Nearly one million people could have their homes repossessed because they do not have a plan to pay off their interest-only mortgages.